Roche lines up Alzheimer's therapy and blood-test showcase for Boston congress
The Swiss drugmaker will present 16 abstracts across a brain-penetrant antibody, an oral inflammation-targeting pill and blood diagnostics, though no results have been disclosed.
Roche is preparing to put both its Alzheimer's drug pipeline and its diagnostics business in front of the field at next week's CTAD Congress in Boston. The company said on 10 November 2026 that it will present 16 abstracts at the meeting, which runs from 16 to 19 November.
The therapeutic material centres on trontinemab, which uses Roche's Brainshuttle technology. The company will show Phase Ib/IIa data and describe the design of PrevenTRON, a Phase III study in preclinical Alzheimer's disease. Roche said recruitment into PrevenTRON has started, which places the molecule in a late-stage programme aimed at people before symptoms appear.
A separate line of work involves RG6434, an oral NLRP3 inhibitor. Roche will present the Phase II TARBELA-AD trial, which is studying the compound in people with early symptomatic Alzheimer's disease.
Roche's diagnostics arm will also be on the programme, with clinical and health-economic data on the Elecsys pTau217 and pTau181 blood tests. Pairing treatment and testing data in one congress slate reflects the company's presence on both sides of the Alzheimer's care pathway.
The announcement does not provide specific results, endpoints, safety findings or regulatory status for any of the products. The commercial significance of the data will depend on what is actually shown in Boston.
Why it matters
- Enrolment in PrevenTRON shows Roche is advancing trontinemab into a preclinical population, a choice that will influence future evidence requirements and labelling discussions.
- Health-economic data on the Elecsys blood tests will interest market-access teams weighing how biomarker testing could fit into Alzheimer's care pathways.
- With no efficacy, safety or regulatory details released, firm conclusions must wait for the CTAD presentations.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
